fda bpc-157 not approved human use statement Approval Status: Is It for Use? Peptide BPC-157 - Does It

Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients

It has potential therapeutic benefits, including gastrointestinal protection, wound and tissue healing, muscle recovery, anti-aging effects, and even possible cardiovascular and neurological benefits

When prescribed for appropriate patients and monitored by a licensed medical provider, wellness treatments can be safe and effective

GLP-1 receptor agonists such as Saxenda and Wegovy work, with clinical trial evidence behind them roughly 6% and 16% body weight reduction respectively over 68-week trials